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Dynamic mutations involve expansion of the number of repeat units
consisting of three or more nucleotides in tandem (i.e. adjacent to one
another) present in a gene or in its neighborhood. These repeats may occur
in different genes and may code for different aminoacids.
According to expansions sizes, it is possible to have unaffected individuals
that are carriers of a pre-mutation. Instability of triplet repeat size can lead
to gradual expansion through generations, a phenomenon called
anticipation. Genetic anticipation is characterized by the reduction in the
age of disease onset and by a worsening of symptoms in affected
individuals in successive generations.
This work describes dynamic mutations giving emphasis on triplet repeats
diseases, making the parallel with disease anticipation. Treatment
strategies that have been developed during the last years are also
discussed.
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INTRODUCTION
Eukaryotic genomes contain several types of repetitive sequences like long
repeats, satellite DNA and many other sequences of diverse sizes and
repetitive levels not yet classified [1,2]. Repeats of simple sequences or
microsatellites are present in high abundance in many prokaryotic and
eukaryotic genomes [3,4]. According with McMurray [5] repetitive DNA
sequences constitute 30% of the human genome and, in most species,
changes in the length of repetitive DNA during evolution give rise to
species diversity.
In the beginning of 90th decade, the identification of a novel class of
mutations leading to diseases gave rise to considerable enthusiasm in the
scientific community [6]. This type of mutations is the presence of
trinucleotide repeats that belong to the family of microsatellites also
known as repeat sequences in tandem. This type of repetitive DNA shows
high degree of mutation, being present in prokaryotic and eukaryotic
genomes [2,7].
Genetic instability of triplet repeats is a trait present in certain types of
hereditary neurological diseases [8]. There are around twenty neurologic
and neuromuscular diseases caused by trinucleotides repeat expansions,
but their development mechanisms are still not known [5,9]. Triplet repeat
disorders include Myotonic Dystrophy types (1, 2, 3, 6, 7 and 8),
Spinocerebellar Ataxia, Huntington Disease, X Fragile Syndrome,
Friedreich Ataxia, Haw River Syndrome and Jacobsen Syndrome. The
cause of these disorders has been described as the expansion of the number
of triplet repeats CTG-CAG, CGG-CCG or GAA-TTC in associated genes
[9,10]. Symptoms will be present as soon as the individual accumulates a
determined number of repeats that results from the somatic instability of
the expanded triplet. Long et al. [11] determined the extent of somatic
instability of the GAA repeats in several tissues from 15 patients with
Friedreich's ataxia. In this work, researchers observed significantly longer
GAA tracts detected in heart and pancreas. Moreover, analysis of the GAA
repeat length in lymphocytes collected over a span of 7-9 years, showed
progressive expansions of that repeat with maximum gain of
approximately 9 repeats per year [11].
This instability of the expanded triplet is responsible for the increase in the
number of repeats from one generation to the next. Consequently, the age
of symptoms onset in these disorders follows an unusual genetic pattern
called anticipation, where the disease becomes more severe and assumes
earlier expression in each generation [9,10]. This anticipation phenomenon
has been described in genetically complex disorders, like bipolar affective
disorder, schizophrenia, Crohn’s disease and psoriasis [12,13]. All triplet
repeat disorders show anticipation [14] and a significant correlation
between age at onset of the disease and length of the expanded repeat is
observed [11,15].
Despite last decade efforts of researchers in the development of treatments
for unstable repeat expansions, triplet repeat diseases are still not curable
[6].
MATERIALS AND METHODS
The present revision was done through search of scientific publications,
revision papers, books and thesis. The search was performed using the
websites: Pubmed, B-On, SciELO, Science Direct, as well as libraries of O
´Porto Medicine Faculty (FMUP) and Fernando Pessoa University.
Keywords used in the search were: “human genome”, “genetic
anticipation”, “diseases of trinucleotides repeats”, “neurodegenerative
disorders”, “spinocerebellar ataxia”, “Huntington disease”, “X fragile
disease”, “myotonic dystrophy”, “Friedrich ataxia”, “X fragile associated
ataxia”.
DYNAMIC MUTATIONS
Mutations are permanent cell genome changes in a certain DNA sequence
that are transmitted to daughter cells. These changes can be of a single
nucleotide or more extensive.
Dynamic mutations involve the expansion of the repetitive unit number
present in a certain gene or in its neighborhood, consisting of three or
more nucleotides in tandem. The presence of these repetitive sequences
makes more likely the occurrence of DNA polymerase slippage, leading to
the insertion of extra nucleotides in that area during DNA replication [13].
Tandem repeats are usually classified in microsatellites (1-6 bps),
minisatellites (6-24 bps, and in certain cases longer) and classic satellites.
These repeats have been found in regulatory regions of eukaryotic genes,
interacting with transcription factors [4].
The extent of triplet repeats propagation varies from genome to genome,
and results from mistakes and rearrangements during replication. In this
perspective, a big portion of repetitive genomic DNA can be considered as
having no role, however the presence of tandems can be related with a
biological function. As an example, long tandem repeats represent a big
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function in heterochromatin being involved in the formation and function
of the centromere [1].
Polymorphic triplet repeats are better tolerated than repeats of untranslated
sequences of dinucleotides and tetranucleotides because the change does
not affect sequence open reading frame [7].
In normal individuals, chromosomes have a certain number of triplet
repeats (usually 5-37), that are polymorphic in the general population
[10]. The increase in the number of triplet repeats to 50-120 is associated
to some diseases/syndromes [8].
According to Krzyzosiak et al. [6] each disease is associated with
mutations in only one gene that would trigger a pathogenic process
through aberrant gene expression and toxic properties of mutant proteins.
The same work revealed that mutant proteins and corresponding RNAs
can act in parallel exhibiting the pathogenic effects in an independent
fashion [6].
TRINUCLEOTIDES REPEATS DISEASES
Triplet repeat diseases constitute the most diverse and interesting class of
microsatellites present in genomic sequences [16,17]. From the 64 triplets
of nucleotides, 4 are classified as mononucleotides repeats (AAA, TTT,
GGG, or CCC) [16]. Triplet repeat AGC is considered similar to GCA or
CAG. The same happens with all other triplet repeats [16].
Density and distribution of triplet repeats
Subramanian and collaborators [3] analyzed human DNA sequences using
a program designed to detect the abundance and distribution of triplet
repeats in coding and non-coding portions of the genome. Repeat density
was calculated for each type of triplet (bp/Mb) in each chromosome.
Chromosome 1 showed the biggest number of triplet repeats while
chromosome Y showed the lowest. Repeat AAT was the one having the
highest density in the whole genome. The size average of this repeat was
282 bp/Mb per sequence. In second place were AAC (average of 193 bp/
Mb), AAG and AGG (both with 77 bp/Mb). ACG repeat registered the
lowest density (average varied between 0 and 1 bp/Mb) in most
chromosomes, followed by ACT as the second less dense with an average
of 9 bp/Mb [3].
The number of repeats is inversely proportional to occurrence. It was
observed the following distribution of triplets repeats: AAT (26 037),
AAC (18 707), followed by AGG (10 245) that registered highest number
of occurrences for 4 repeats in tandem [3].
Distribution of triplet repeats in several genomic
regions
Analysis of triplet repeats type occurrence was conclusive in terms of
abundance of repeats in introns compared with the occurrence in exons or
untranslated regions [3,16].
AAT and AAC repeats were the most abundant and ACG and ACT
repeats revealed poor abundance in all analyzed regions [3,16]. In exons,
triplet repeats, like AGC, AGG and CCG, are respectively the most
abundant, while in untranslated regions, triplets like CCG and AAT
followed by AAC showed predominant occurrence. However, these levels
are very low when compared with its levels in exonic regions [3,16].
Association of triplet repeats with genes
Subramanian et al. [3] showed that around 2135 genes contained at least
one type of triplet in exons having a minimum of four repeats in tandem.
From these 2135 genes, 171 had length repeats of at least 30 bps. The
same study revealed that genes had mainly AGC and CCG repeats.
Moreover, repeats AAC, AAT, AAG, ACC and ATC are not
predominantly found in genes, and ACT or ACG repeats are completely
absent in genes [3,16].
Triplet repeats and the promoter region
Analysis of 500 bp gene promoter sequences revealed the existence of
preferred association of certain repeats with these regulatory sequences.
Most promoter regions contain CCG tandem repeats [3]. The second most
abundant type of repeat in promoter regions is AGG followed by AAT and
AAC [3,16]. The abundance of the last two repeats can be explained on
the basis of its abundance in the whole genome, but this is not true for
CCG and AGG repeats [3]. For this reason, it is not easy to explain the
predominance of CCG triplets in promoters, however as promoter regions
possess CpG islands, it is expected that most promoter sequences have
CCG repeats [3].
From the 269 genes that had at least one triplet repeat in the promoter
region, none had ACT repeats [3].
Triplet repeats in human transcription
The big abundance of some triplet repeats in cells genome raises questions
about the roles of these sequences in transcription. Triplet repeats differ in
length, and the level of gene expression depends on the secondary
structures that these regions can form as well as on the presence of repeats
that disrupt the homogeneity of the repeat [6,18].
In fact, a study showed that the human genome includes more than 32000
extensions of uninterrupted triplet repeats composed of six or more repeat
units [7]. Even human exons, that represent less than 3% of genomic
sequences, show a maximum of 1030 extensions of triplet repeats. These
were identified in exons of 878 genes [6]. Triplet repeats that are highly
present in exons are CNG (where N represents any nucleotide), CGA and
AGG [6,18]. CTT, CAT, CAA, TAA and TTA repeats are present in lower
amounts [6,18].
Triplet repeat sequences rich in AT, like CTT, AAC and AAT are
particularly sub-represented in exons while repeats rich in GC (CGG,
CAG and CCG) are highly abundant suggesting a functional role of these
sequences [7,16]. Moreover, shorter sequences are more prevalent, and the
triplet repeat frequency decreases exponentially with its length [6].
In exons, 60% of triplet repeat sequences are located in the open reading
frame and repeat codons are translated into poly-glutamine, poly-alanine,
poly-glutamate and poly-leucine [7]. CCA, CAG, CTG, CCT, AGG, AAG
and ATG triplets appear frequently in the open reading frame region [6].
Besides these, 28% of gene repeats are located in the 5’ untranslated
region (CCG and CGG are the most frequent with an abundance of 52%
and 62%, respectively) and 13% in the 3’ untranslated region (the most
abundant are triplet repeats rich in AT) [6].
Functional studies have been done to clarify the roles of triplet repeats
present in genes. Krzyzosiak and collaborators [6] saw that these genes
code for proteins involved in transcription or proteins that interact with
nucleic acids.
According to Sobczak et al. [7] triplet repeats can play an important role
in the regulation of several cellular processes, like DNA repair during
replication and diverse stages in gene expression.
RNA structural types in triplet repeats
Functional analysis of triplet repeats in RNAs, through
oligoribonucleotides structures (ORNs) formed by several specific triplet
repeats has been investigated in different experimental conditions. The
first types of ORNs analyzed was GNC. All these ORNs assumed stable
hairpin structures [6,18]. The hairpin formed with GNC repeats was
composed of periodic repetition of base pairs C-G and G-C, and the loop
of the hairpin was formed by any four or seven nucleotides [6].
Except for CGG hairpin, all other CNG repeats form slippery hairpins,
meaning that they tend to form alternative alignments unless a
conformation by G-C clamp is present [6].
A comparative analysis of 20 triplet repeats showed that AGG and UGG
tend to form quadruplex structures that are considered the most stable
ones, followed by CGA, CGU and CNG repeats that give rise to hairpins
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that are more stable than the ones formed by UAG, AUG, UUA, CUA and
CAU repeats. CAA, UUG, AAG, CUU, CCU, CAA and UAA repeats do
not form any secondary structure [7,18]. The analysis of hairpin and
quadruplex repeats, with the help of biophysical methods revealed the
following order of CNG repeat stability: CGG>CAG>CUG>CCG. The
stability of quadruplex structures of AGG and UGG triplets is similar
[7,18].
Recent work studied the structure and dynamics of RNA repeat
expansions responsible for the development of Huntington disease and
Myotonic Dystrophy type 1 [19]. Researchers analysed the structures of
two RNA constructs containing three copies of r(CAG) or r(CUG) motif
by nuclear magnetic resonance spectroscopy. The 1×1 internal loops of
r(3×CAG) were stabilized by one-hydrogen bond AA pairs, while those of
r(3×CUG) preferred one or two hydrogen bond UU pairs [19]. Chen et al.
[19] observed that the loop regions of RNA structures are dynamic.
Triplet repeat and its interaction with proteins
Research on proteins resulting from trinucleotide sequences present in
triplet repeats disorders has a lot of interest in the study of toxic features
of mutant transcripts [20]. Performed studies were mainly focused on the
identification and structural characterization of proteins resulting from
triplet repeats [20].
Cellular proteins that are involved in the formation or processing of
hairpins are pointed out as one of the causes of triplet repeats expansion
[20].
Using mouse models, it was seen that the MutSβ protein, responsible for
identifying mismatches, is the causing agent of triplet expansion in
Huntington disease and Myotonic Dystrophy 1 [20,21]. Most inheritable
somatic expansions are blocked by knockout of Msh2 or Msh3 genes that
code for the two subunits of MutSβ protein [20,21]. Studies performed in
mice, showed that mismatch repair done by complex Msh2-Msh3 is
essential for CAG repeat expansion in germ line and somatic cells [22].
This supports the hypothesis of mismatch repair being an important source
of expansion especially in non-proliferative tissues where replication is
low [20,21].
Types of triplet repeat disorders
The number of neurodegenerative disorders resulting from triplet repeats
is increasing, as well as the complexity of its molecular pathogenesis [23].
More than 20 different genes containing unstable triplet repeats are
responsible for the pathogenesis of human neurological diseases. Repeats
like CTG, CGG, GAA and CAG, are source of degenerative changes
leading to Myotonic Dystrophy type 1 (MD1), Fragile X associated ataxia
(FXTAS), Friedreich ataxia (FRDA), as well as Huntington disease (HD)
and several types of spinocerebellar ataxias (SCAs) [6,24].
There are two main types of triplet repeats diseases. The first type
corresponds to the group of disorders where the expanded triplet repeat is
translated, usually including poly-glutamine or poly-alanine homorepeats.
In the second type, triplet repeats are present in non-coding regions of the
gene. These repeats can be expressed at the mRNA level (affecting
expression levels of coded proteins) but are not translated, having no
effect on protein structure. However, sometimes, the produced mRNA can
be translated, giving rise to highly repetitive peptides of different length
and aminoacid content. This might be the crucial step to the formation of a
toxic homopolypeptide that can lead to the development of the pathology.
Type 1: Diseases of translated triplet repeats
Type 1 of triplet repeats diseases involves the translation of the expanded
sequence leading to the synthesis of a chain of glutamines or alanines.
This results in the formation of protein aggregates inside the cell [6,23].
These aggregates lead to the appearance of the toxic function of the
mutant protein [23].
In the case of poly-glutamine repeats, the CAG repeat is highly unstable
and consequently there is a high level of polymorphism among affected
individuals and in different tissues.
These proteins lead to highly stable β-rich amyloid-like protein inclusions
[25], that can accumulate in the nucleus or the cytoplasm. Since these
poly-glutamine expansion proteins usually interact with several other
proteins, the produced aggregates contain diverse proteins like
chaperones, ubiquitin and other poly-glutamine containing proteins,
making them unable to perform their functions [25]. As soon as they form
large inclusions, these proteins become resistant to degradation. These
expansion proteins are usually involved in the regulation of neurogenesis
or transcription [26].
Concerning poly-alanine repeats, the extension of these tracts occurs by
unequal homologous recombination during meiosis, while other disease
expansions extend because of DNA polymerase slippage [27]. These
extensions result in structural changes in the repeat peptide that is
dependent on its length. Big repeat length usually pushes the peptide to
degradation or aggregation. Longer repeats tend to aggregate due to the
formation of stable β-sheets, that are resistant to degradation [28]. These
dense aggregates mis-localize to the cytoplasm and can contain the mutant
as well as the wildtype peptide, precluding its normal function.
Most proteins having pathogenic poly-alanine repeat expansions act as
transcription factors, except for PABP-2 that controls the length of
polyadenylate tails added during mRNA processing.
The number of triplet repeats that leads to the development of the
pathology differs from gene to gene. Moreover, in most cases the repeated
sequence shows somatic instability, meaning that it has a strong
probability of expansion. The speed of expansion of these triplet repeats
also varies according with the gene.
Table 1 lists a group of this type of disorders with the corresponding
repeat sequence, its location and the length of the repeat that leads to
disease development.
Table 1 Localization, triplet repeat sequence, its location and the length of the repeat that leads to type 1 repeat diseases.
Disease (poly-glutamine) Sequence Number of repeats
(normal)
Number of repeats
(disease)
Localization
Dentatorubral-pallidoluysian atrophy (DRPLA) CAG 6-35 49-88 ATN1 (exon 5)
HD CAG 6-29 38-180 HTT (exon 1)
SCA1 CAG 6-39 41-83 ATXN1 (exon 8)
SCA2 CAG <31 32-200 ATXN2 (exon 1)
Machado-Joseph disease (SCA3) CAG 12-40 52-86 ATXN3 (exon 8)
SCA6 CAG <18 20-33 CACNA1A (exon 47)
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SCA7 CAG 4-17 >36 to >460 ATXN7 (exon 3)
SCA17 CAG 25-42 45-66 TBP (exon 3)
Spinal Muscular Bulbar Atrophy (SMBA) CAG 13-31 40 AR (exon 1)
Disease (poly-alanine) Sequence Number of repeats
(normal)
Number of repeats
(disease)
Localization
Synpolydactyly (SPD II) GCG 15 >21 HOXD13 (exon 1)
Hand-foot genital syndrome (HFGS) GCG 12 >17 HOXA13 (exon 1)
Cleidocranial dysplasia (CCD) GCG 17 >26 RUNX2 (exon 1)
Holoprosencephaly disorder (HPE) GCG 9 - ZIC2 (exon)
Congenital central hypoventilation syndrome (CCHS) GCG 20 - PHOX2B (exon 3)
ARX-nonsyndromic X-linked mental retardation (XLMR) GCG 16 >17 ARX (exon 2)
Oculopharyngeal Muscular Dystrophy (OPMD) GCG 10 >11 PABPN1 (exon 1)
Type 2: Diseases of untranslated triplet repeats
In type 2 repeats disorders the triplet sequence is present in non-coding
regions of genes [23] and can be expressed at mRNA level. These mRNAs
form stable structures that can damage cells. But their main toxicity comes
from the fact that although they are not translated, can affect the
expression levels of coded proteins, since mutant RNAs can bind specific
proteins and inhibit their normal functions. This model has been proposed
for several triplet repeat diseases such as Myotonic Dystrophy type 1 [29]
and Fragile X Tremor Ataxia Syndrome [30,31].
Another proposed disease mechanism is supported by the fact that these
expansion repeats, although start codons are absent, sometimes suffer
aberrant translation (repeat-associated non-AUG (RAN) translation),
giving rise to toxic polypeptides with highly repeated sequences [30-32].
These peptide products may contribute to cell death through a gain of
function toxicity.
Table 2 summarizes the expanded sequence, location and the average
number of repeats required for the development of several untranslated
triplet repeat disorders.
Table 2 Localization, repeat sequence and number of repeats that leads to several untranslated triplet repeats diseases.
Disease Sequence Number of repeats
(normal)
Number of repeats
(disease)
Localization
Myotonic Dystrophy type 1 (MD1) CTG 5-37 <50 DMPK (3′ UTR)
MD2 CCTG <30 75-11000 CNBP (intron 1)
Fragile X mental retardation (FRAX-E) GCC 4-39 >200 AFF2 (5′ UTR)
Friedreich ataxia (FRDA) GAA 5-30 70-1000 FXN (intron 1)
Fragile X Syndrome (FXS) CGG 6-50 200-4000 FMR1 (5′ UTR)
Huntington disease-like 2 (HDL2) CTG 6-27 36-57 JPH3 (exon 2A)
Spinocerebellar ataxia type 8 (SCA8) CTG 15-34 89-250 ATXN8OS (3′ UTR)
SCA10 ATTCT 10-29 400-4500 ATXN10 (intron 9)
SCA12 CAG 7-28 66-78 PPP2R2B (5′ UTR)
Experimental Therapies directed against Triplet
Repeats
Development of selective therapeutic agents is based on differences
between normal and mutant transcripts concerning repeat sequence length
and assumed secondary structures [6].
The most promising approaches of possible treatments aim lowering
mutant protein by targeting DNA or RNA transcripts.
RNA targeting has been developed through three main strategies directed
against triplet RNA repeats: RNA interference (RNAi), antisense
oligonucleotides (ASOs) or using splicing inhibitors.
The first one is based on mutant transcripts degradation using interfering
RNA (iRNA) since these RNA molecules bind to mRNA in the
cytoplasm, leading to its degradation by the RNAse enzyme argonaute 2
[33]. This strategy has been applied in treatment of Huntington disease,
and it was seen that a single treatment might permanently lower the levels
of huntingtin [34].
ASOs act in a similar way, catalysing degradation of mRNA transcripts by
RNAse H, and consequently leading to reduction of coded protein [6].
Kordasiewicz et al. [35] observed an 80% reduction in huntingtin
transcript levels using this strategy [35].
According to the mechanism of action, these antisense reagents are called
Cutters since they attach to complementary targets and induce their
cleavage.
Splicing inhibitors have been used in the treatment of spinal muscular
atrophy. The purpose of these molecules is to increase the synthesis of
SMN protein by stopping alternative splicing that leads to truncated SMN
protein and the development of neuromuscular degeneration [36].
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Targeting DNA with the goal of reduction of protein expression can be
performed through two approaches: zinc finger proteins and CRISPR/
Cas9.
Zinc finger proteins form a structural motif able to bind DNA and hence
might reduce coded protein levels. This strategy has been used to reduce
levels of mutant huntingtin protein in animal models [37]. However, since
these proteins lead to the formation of non-native molecules, there is the
chance of development of immune reactions [37].
CRISPR/Cas9 is present in the bacterial immune system and its role is to
cleave foreign DNA. In a recent study, this novel strategy was used and
allowed to recover normal phenotype in myogenic cells derived from
fibroblasts of patients with Myotonic Dystrophy type 1 [38]. The aim of
the developed strategy was to eliminate the toxic mutant repeats.
Researchers used the CRISPR/Cas9 gene-editing system, and were able to
remove the repeat expansions, therefore preventing nuclear foci formation
and splicing alterations [38]. The advantage of this approach when
compared with previously described strategies is that affected cells can be
permanently reverted to a normal phenotype. Permanent inactivation of
Huntington’s disease mutation was also achieved in fibroblasts of a patient
using this approach [39].
In some triplet repeat diseases, the expanded repeat leads to reduction of
gene expression. This is observed in patients having Friedreich’s ataxia or
spinal muscular dystrophy, that show a reduction in the expression of
respectively FXN or SMN proteins. ASOs have also been used in cell
lines of patients having Friedreich’s ataxia and spinal muscular dystrophy
to increase gene expression [40,41]. The proposed mechanism of action of
ASOs in increasing gene expression, involves the binding of these
compounds to the expanded repeat and expected blockage of the expanded
RNA that inhibit recognition of DNA, prevent R-loop formation and allow
more gene expression [40].
An important issue in therapy directed to triplet repeats is the need for
gene and allele selectivity. Although there are numerous mRNA
containing triplet repeats in the human transcriptome, the specific
inhibition of mutant gene expression having as target certain repeat
regions is a promising therapy strategy for these kind of diseases [6].
Agents have been developed that are able to distinguish between RNA
hairpin structures formed by wildtype and mutant RNAs, since they differ
in length and consequently diverge in stability. Hu et al. [42] used peptide
nucleic acid (PNA) peptide conjugates and locked nucleic acid (LNA)
oligomers for specific reduction of mutant huntingtin expression [42].
PNAs are a class of DNA/RNA mimic with an uncharged amide
backbone, whose advantage is the lack of charge-charge repulsion of
RNA/DNA or RNA/RNA duplexes, when these agents bind
complementary RNA sequences. In this way, there is an increase on the
affinity of PNA hybridization and the recognition of target sequences. On
the other hand, LNAs are RNA analogs containing a methylene bridge
between the 2'-oxygen and 4'-carbon of the ribose. This bridge reduces the
conformational flexibility of ribose and confers outstanding affinity to
complementary hybridization. These scientists observed that these two
strategies can confer potent allele-selective inhibition of mutant
Huntington gene expression [42].
Another strategy recently tested was based on the hypothesis that the
epigenetic modifications close to GAA repeats present in Friedreich's
ataxia can be reversed by pharmacological modulation during somatic cell
reprogramming [43]. In this work, researchers reprogrammed Friedreich's
ataxia fibroblasts into induced pluripotent stem cells in the presence of
various small molecules that target DNA methylation and histone
acetylation and methylation. Treatment of these stem cells with two
compounds (sodium butyrate and Parnate), led to an increase in
expression of the frataxin gene which persisted for several passages [43].
However, they observed that prolonged culture of those epigenetically
modified cells resulted in progressive expansion of triplet repeats and
consequent decrease of gene expression.
CONCLUSION
Over 3 billion bp of DNA constitute the human genome and a
considerable part is formed by repetitive DNA [44]. This repetitive DNA
includes microsatellites, telomere repetitive DNA sequences, centromeres
and regions of chromosome heterogeneous DNA [44].
It is quite frequent the appearance of repetitive DNA that consists of
repetition of triplets that can be present in several genes and code several
aminoacids [44]. These triplet repeats can appear in enzymes, hormone
receptors or non-coding regulatory sequences. These repeats can disrupt
protein structure or interfere with cellular activities like methylation and
imprinting, protein degradation through ubiquitination, and processing
through proteasome, as well as gene activation and inactivation [44].
Triplet repeats can appear during somatic or germline cell division as well
as in non-dividing cells [22]. The instability of triplet repeats can lead to
gradual expansion of the repeat that might result in disease [44].
Expansion of these repetitions is particularly important in neurons and has
an important role in brain aging, as well as in the appearance and
progression of diseases in mice and humans [22].
Expansion of triplet repeats was first identified as happening during DNA
replication, however, studies using bacteria, yeasts and mice showed that
it can also occur during DNA repair, transcription and in recombination
[22]. However, mechanisms involved in expansion are still only slightly
understood [22].
There are even cases of bigger expansion or contraction of triplet repeats
depending on the kind of repeat and on its parental origin [44].
Expansion sizes can give rise to non-affected carriers (permutation) and,
as the expansion size increases through following generations, can lead
disease with increase in severity of clinical symptoms and age of onset
[44].
Triplet repeat expansion over generations leads to the phenomenon of
anticipation [44]. Studies in families with myotonic dystrophy or
Huntington disease have shown strong evidences that anticipation has a
biological and genetic basis in the form of the rise in triplet repeats
number. This number increases in following generations showing an
inverse correlation between the number of repeats and the age of
symptoms onset [45].
In cases of genetic anticipation, being female or male influences disease
severity. For example, in Huntington disease descendants of affected
males have an earlier onset of the disease when compared with
descendants of affected women [45].
Most triplet repeats diseases have parental origin, since it is very rare the
occurrence of de novo mutations [44]. However, the existence of specific
DNA replication and repair mechanisms having the goal of detecting
mistakes and repairing DNA, can potentially explain why some persons
are more likely to suffer expansions or contractions of triplet repeats [44].
Several treatment strategies have been developed for this group of
disorders, some directed to triplet repeat in DNA and others aiming the
transcribed RNA. Nowadays, the main concern is to target mutant gene
expression, without damaging transcription of the wildtype gene.
REFERENCES
1. Boeva V, Regnier M, Papatsenko D, et al. Short fuzzy tandem
repeats in genomic sequences, identification, and possible role in
regulation of gene expression. Bioinformatics 2006;22:676-84.
2. Huntley MA, Golding GB. Neurological proteins are not enriched for
repetitive sequences. Genetics 2004;166:1141-54.
3. Subramanian S, Madgula V, George R, et al. Triplet repeats in human
genome: distribution and their association with genes and other
genomic regions. Bioinformatics 2003;19:549-52.
4. McConnell R, Middlemist S, Scala C, et al. An unusually low
microsatellite mutation rate in Dictyostelium discoideum, an
organism with unusually abundant microsatellites. Genetics
2007;177:1499-507.
Cardoso IL, et al
8 J clin gen genomics. Vol.1 No.1 March-2018
5. McMurray CT. Mechanisms of trinucleotide repeat instability during
human development. Nat Rev Genet 2010;11:786-99.
6. Krzyzosiak WJ, Sobczak K, Wojciechowska M, et al. Triplet repeat
RNA structure and its role as pathogenic agent and therapeutic target.
Nucleic Acids Res 2012;40:11-26.
7. Sobczak K, Michlewski G, Mezer M, et al. Structural diversity of
triplet repeat RNAs. J Biol Chem 2010;285:12755-64.
8. Jakupciak JP, Wells RD. Genetic instabilities in (CTG.CAG) repeats
occur by recombination. J Biol Chem 1999;274:23468-79.
9. Jung J, van Jaarsveld MT, Shieh SY, et al. Defining genetic factors
that modulate intergenerational CAG repeat instability in Drosophila
melanogaster. Genetics 2011;187:61-71.
10. Jakupciak JP, Wells RD. Genetic instabilities of triplet repeat
sequences by recombination. IUBMB Life 2000;50:355-9.
11. Long A, Napierala JS, Polak U, et al. Somatic instability of the
expanded GAA repeats in Friedreich’s ataxia. PLoS One 2017;12.
12. Deighton C, Criswell LA, Lum RF, et al. Ages of onset suggestive of
genetic anticipation in rheumatoid arthritis multicase sibships can be
explained by observational bias. Rheumatology 2007;46:120-3.
13. Lima IVM. Repetições CAG: candidatos na génese das psicoses
funcionais. Rev Bras Psiquiatr 1999;21:23-6.
14. Shekari Khaniani M, Aob P, Ranjouri M, et al. Molecular analysis
and prevalence of Huntington disease in northwestern Iran. Turk J
Med Sci 2017;47:1880-4.
15. Young E, Sloan J, Riper K. Trinucleotide repeats are clustered in
regulatory genes in Saccharomyces cerevisiae. Genetics
2000;154:1053-68.
16. Calabrese PP, Durrett RT, Aquadro CF. Dynamics of microsatellite
divergence under stepwise mutation and proportional slippage/point
mutation models. Genetics 2001;159:839-52.
17. Rolfsmeier M, Dixon M, Pessoa-Brandão L, et al. Cis-elements
governing trinucleotide repeat instability in Saccharomyces
cerevisiae. Genetics 2001;157:1569-79.
18. Chen JL, Fountain MA, Yildirim I, et al. Structure and dynamics of
RNA repeat expansions that cause Huntington’s disease and
Myotonic Dystrophy type 1. Biochemistry 2017;56:3463-74.
19. Stevens J, Lahue E, Li G, et al. Trinucleotide repeat expansions
catalyzed by human cell-free extracts. Cell Research
2013;23:565-72.
20. Pinto RM, Dragileva E, Kirby A, et al. Mismatch repair genes Mlh1
and Mlh3 modify CAG instability in Huntington’s disease mice:
genome-wide and candidate approaches. PLoS Genet 2013;9.
21. Liu Y, Wilson SH. DNA base excision repair: a mechanism of
trinucleotide repeat expansion. Trends Biochem Sci 2012;37:162-72.
22. Everett CM, Wood NW. Trinucleotide repeats and neurodegenerative
disease. Brain 2004;127:2385-405.
23. Hou M-H, Robinson H, Gao Y, et al. Crystal structure of
actinomycin D bound to the CTG triplet repeat sequences linked to
neurological diseases. Nucleic Acids Res 2002;30:4910-7.
24. La Spada AR, Weydt P, Pineda VV, et al. Frontiers in neuroscience
Huntington’s disease pathogenesis: mechanisms and pathways. In:
Neurobiology of Huntington’s disease: Applications to Drug
Discovery; Lo DC, Hughes RE. 2011.
25. Muragaki Y, Mundlos S, Upton J, et al. Altered growth and
branching patterns in synpolydactyly caused by mutations in hoxd13.
Science 1996;272:548-51.
26. Cohen MMJr. Holoprosencephaly: clinical, anatomic, and molecular
dimensions. Birth Defects Res. Part A Clin Mol Teratol
2006;76:658-73.
27. Shibata A, Machida J, Yamaguchi S, et al. Characterisation of novel
runx2 mutation with alanine tract expansion from Japanese
cleidocranial dysplasia patient. Mutagenesis 2016;31:61-7.
28. Goodwin M, Mohan A, Batra R, et al. MBNL sequestration by toxic
RNAs and RNA misprocessing in the Myotonic Dystrophy brain.
Cell Rep 2015;12:1159-68.
29. Boivin M, Willemsen R, Hukema RK, et al. Potential pathogenic
mechanisms underlying Fragile X Tremor Ataxia Syndrome: RAN
translation and/or RNA gain-of-function? Eur J Med Gen 2017;
S1769-7212(17):30396-8.
30. Glineburg MR, Todd PK, Charlet-Berguerand N, Sellier C. Repeat-
associated non-AUG (RAN) translation and other molecular
mechanisms in Fragile X Tremor Ataxia Syndrome. Brain Res
2018:300064-7.
31. Baňez-Coronel M, Aythan F, Tarabochia AD, et al. RAN translation
in Huntington disease. Neuron 2015;88:667-77.
32. Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA
silencing. Nat Rev Mol Cell Biol 2008;9:22-32.
33. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in
Huntington’s disease. Lancet Neurol 2017;16:837-47.
34. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained
therapeutic reversal of Huntington’s disease by transient repression
of huntingtin synthesis. Neuron 2012;74:1031-44.
35. Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease.
SMN2 splicing modifiers improve motor function and longevity in
mice with spinal muscular atrophy. Science 2014;345:688-93.
36. Agustin-Pavón C, Mielcarek M, Isalan M, et al. Deimmunization for
gene therapy: host matching of synthetic zinc finger constructs
enables long-term mutant huntingtin repression in mice. Mol
Neurodegener 2016;11:64.
37. Provenzano C, Cappella M, Valaperta R, et al. CRISPR/Cas9-
mediated deletion of CTG expansions recovers normal phenotype in
myogenic cells derived from Myotonic Dystrophy 1 patients. Mol
Ther Nocleic Acids 2017;9:337-48.
38. Shin JW, Kim KH, Chao MJ, et al. Permanent inactivation of
Huntington’s disease mutation by personalized allele-specific
CRISPR/Cas9. Hum Mol Genet 2016;25:4566-76.
39. Li L, Shen X, Liu Z, et al. Activation of frataxin protein expression
by antisense oligonucleotides targeting the mutant expanded repeat.
Nucleic Acid Ther 2018;28:23-33.
40. Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal
muscular atrophy. Nat Neurosci 2017;20:497-9.
41. Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant
huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic
acid and small interfering RNA. Ann N Y Acad Sci
2009;1175:24-31.
42. Polak U, Li Y, Butler JS, et al. Alleviating GAA repeat induced
transcriptional silencing of the Friedreich’s ataxia gene during
somatic cell reprogramming. Stem Cells Dev 2016;25:1788-800.
43. Lutz RE. Trinucleotide repeat disorders. Semin Pediatr Neurol
2007;14:26-33.
44. Polito J, Rees R, Childs B, et al. Preliminary evidence for genetic
anticipation in Crohn’s disease. Lancet 1996;347:798-800.
 
Trinucleotide repeat diseases - antecipation diseases.
J clin gen genomics. Vol.1 No.1 March-2018 9
